Abrdn Life Sciences Investors (NYSE:HQL) Sees Large Growth in Short Interest

Abrdn Life Sciences Investors (NYSE:HQL) was the recipient of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 74,100 shares, a growth of 17.2% from the October 31st total of 63,200 shares. Based on an average trading volume of 74,100 shares, the days-to-cover ratio is presently 1.0 days.

Abrdn Life Sciences Investors Stock Performance

NYSE HQL traded up $0.09 on Tuesday, reaching $14.38. The company had a trading volume of 84,109 shares, compared to its average volume of 92,828. Abrdn Life Sciences Investors has a fifty-two week low of $12.05 and a fifty-two week high of $15.90. The business has a 50 day moving average of $14.74 and a two-hundred day moving average of $14.68.

Abrdn Life Sciences Investors Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 10th. Investors of record on Thursday, November 21st will be paid a $0.50 dividend. This is a positive change from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.49. This represents a $2.00 dividend on an annualized basis and a dividend yield of 13.91%. The ex-dividend date of this dividend is Thursday, November 21st.

Institutional Trading of Abrdn Life Sciences Investors

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC raised its stake in Abrdn Life Sciences Investors by 2.6% during the 2nd quarter. Commonwealth Equity Services LLC now owns 33,788 shares of the company’s stock worth $479,000 after buying an additional 868 shares during the period. Stephens Inc. AR increased its position in shares of Abrdn Life Sciences Investors by 7.6% during the third quarter. Stephens Inc. AR now owns 12,707 shares of the company’s stock worth $192,000 after acquiring an additional 896 shares in the last quarter. Wedbush Securities Inc. lifted its position in Abrdn Life Sciences Investors by 8.2% in the 2nd quarter. Wedbush Securities Inc. now owns 16,673 shares of the company’s stock valued at $236,000 after acquiring an additional 1,261 shares in the last quarter. Sanctuary Advisors LLC boosted its stake in Abrdn Life Sciences Investors by 11.4% during the 3rd quarter. Sanctuary Advisors LLC now owns 13,256 shares of the company’s stock valued at $183,000 after purchasing an additional 1,355 shares during the last quarter. Finally, Future Financial Wealth Managment LLC bought a new stake in Abrdn Life Sciences Investors during the 3rd quarter worth approximately $30,000. Institutional investors and hedge funds own 32.21% of the company’s stock.

About Abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.